An anti-CTLA-4-TβRII studied in a mouse model of breast cancer demonstrated superior activity against tumors compared to single-agent or combination TGF-β antibody and an anti-CTLA-4 antibody [100]. This evidence concerns the gene CTLA4 and breast carcinoma.